鶹ýӰ

Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

An intratumoral drug-releasing can measure the drug's antitumor effects and could potentially help guide treatment, early data suggest. (Brigham and Women's Hospital, Science Translational Medicine)

Mississippi's cervical cancer death rate . (KFF Health News)

Researchers have developed a novel test that is -- a hard-to-find cancer that accounts for up to 25% of cervical cancer cases. (Montefiore Einstein Cancer Center)

Seagen and Genmab announced that the phase III confirmatory innovaTV 301 trial of tisotumab vedotin (Tivdak) by improving overall survival as second-line therapy versus chemotherapy alone for patients with recurrent or metastatic cervical cancer.

Endometrial cancer risk was , a study in Asian women found. (JAMA Network Open)

showed promise in a small single-arm trial of locally advanced unresectable PD-L1 positive non-small cell lung cancer (NSCLC). (JAMA Oncology)

A was associated with a higher rate of pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy. (Journal of Clinical Oncology)

A commercially available artificial intelligence algorithm was as effective as human readers in . (Radiology)

One in eight cancer patients with no history of depression developed new-onset depression , while half of those with a history had a recurrence. (Cancer Management and Research)

Bristol Myers Squibb of using illegal tactics to maintain its monopoly on pomalidomide (Pomalyst) -- used to treat multiple myeloma -- when it should have faced generic competition. (Reuters)

Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had -- such as infections, bleeding, and inflammation -- but experienced no overall survival benefit. (Blood Advances)

State was tied to overall survival for socioeconomically disadvantaged people with cancer. (JAMA Network Open)

Janssen announced that the phase III MARIPOSA-2 study plus chemotherapy with or without the investigational EGFR inhibitor lazertinib met its primary endpoint by extending PFS when compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC.

A study found that most non-English speakers who call a hospital general information line are on the steps they must take to access cancer care. (Journal of the National Comprehensive Cancer Network).

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.